Fangzhou Inc. 6086

SHANGHAI, China, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has released its 2026 interim report, highlighting continued progress in its “AI + Chronic Disease Services” strategy as the Company advances its positioning as a full-lifecycle personal health service partner. In the first half of 2026, Fangzhou recorded revenue of RMB1.8245 billion, up 22.2% year-on-year, while adjusted ne

SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” platform has been named to the 2026 Fortune China Best Designs list, recognizing the Company’s innovation and application of artificial intelligence in chronic disease management. Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026 Now in its fifth year, F

HONG KONG, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced its interim results for the six months ended June 30, 2026, reporting revenue of RMB 1.8245 billion, a 22.2% year-on-year increase, and adjusted net profit of RMB 18.7 million, up 6.4% from the same period last year. The results reflect the Company’s continued execution of its "AI + chronic care" strategy amid favorable p

SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, further expanding its collaboration with global healthcare company Novo Nordisk to improve access to innovative diabetes treatments through AI-powered chronic disease management services. Chin

SHANGHAI, July 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has been named to the KPMG China Healthcare 50 list, in recognition of its approach for “extending chronic disease management into the home, with trusted long-term care”, and its deep expertise in AI-driven chronic disease management. Fangzhou has been named to the KPMG China Healthcare 50 list Fangzhou's inclusion reflects growing

BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, attended the 2026 Tencent Cloud AI Industry Applications Summit in Beijing, where it showcased its “AI + Chronic Disease Services” digital solution developed in collaboration with Tencent Health. The conference, themed “Agent in Action, Productivity in Motion,” brought together industry leaders, technology developers, and ecosystem p

As global markets are buoyed by optimism surrounding a potential U.S.-Iran deal and the momentum in AI-linked stocks, investor sentiment remains positive across major indices. Despite being an older term, penny stocks continue to offer intriguing opportunities for investors seeking value in smaller or newer companies. These stocks can present significant growth potential when underpinned by solid financials, making them appealing candidates for those looking to uncover hidden value in the...

GUANGZHOU, China, May 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to attend the 2026 Guangzhou Artificial Intelligence and Intelligent Autonomous Systems Innovation Development Promotion Conference (the “Conference”), where the Company was recognized for its technological innovation in “AI + chronic disease services.” Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Prom

SHANGHAI, May 14, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, and Shanghai Tenry Pharmaceutical Co., Ltd. (“Tenry Pharmaceutical”) have entered into a strategic partnership at the 92nd PHARMCHINA in Shanghai, marking a significant step toward advancing AI-powered chronic disease management and broader support across the patient journey. The partnership will combine technological innovation and

WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry Academic and Industry Integration Conference, held from May 6 to 9 in Wuhan. At the health management sub‑forum, Fangzhou presented its innovative “AI+Chronic Disease Service” solutions, addressing some of the most pressing challenges in chronic disease care. AI+H2H Ecosystem Und

SHANGHAI, April 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, published its 2025 Annual Report, following the announcement of its 2025 annual results on March 19, 2026. The report highlights strong revenue growth, a return to full-year profitability and continued execution of Fangzhou’s “AI + chronic care” strategy as the Company advances its position as a trusted, long-term healthcare servic

SHANGHAI, March 26, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, today announced the appointment of Mr. WANG Haijiao as Chief Executive Officer and Executive Director, effective March 26, 2026. Mr. Wang succeeds former CEO Mr. Xie Fangmin and steps into the leadership role following a milestone year for the Company. For the fiscal year 2025, Fangzhou reported a successful financial turnaround, a

SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability, as its AI-enabled chronic disease management model continues to scale. Total revenue rose 30.2% year on year to RMB 3.53 billion in 2025, driven by steady growth in its consumer-facing businesses, including comprehensive medical s

BEIJING, Feb. 28, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has signed a strategic collaboration agreement with Youcare Pharmaceutical Group (悦康药业集团 or “Youcare”) (SH: 688658), a leading integrated pharmaceutical enterprise in China. The partnership aims to accelerate the digital transformation and enhancement of chronic disease services through the application of artificial intelligence (“AI

SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Industry research platform VBData recently highlighted “XingShi” Large Language Model (“XS LLM”) from Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, as one of China’s most anticipated healthcare AI models for 2026. The “XingShi” Large Language Model (“XS LLM”) integrates five intelligent agents — knowledge services, triage, pre-consultation, physician support and electronic medical record

SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, has won the “AI-Powered Future Award” at a high-level industry forum hosted by Tencent Health, underscoring its pioneering efforts in the field of “AI + Chronic Disease Services” and its strong leadership in the digital transformation of the healthcare sector. The award was presented at the “T-Inspire CIO Private Forum,” organized by Tencent